Ashwini Shewade
Overview
Explore the profile of Ashwini Shewade including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
156
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yamshon S, Koff J, Larson M, Kahl B, Casulo C, Lossos I, et al.
Am J Hematol
. 2025 Feb;
100(4):606-615.
PMID: 39918101
Rituximab, gemcitabine, and oxaliplatin (R-GemOx) is a commonly used chemoimmunotherapy regimen for relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), but there are limited real-world data. In a multicenter...
2.
Maurer M, Casulo C, Larson M, Habermann T, Lossos I, Wang Y, et al.
Haematologica
. 2023 Nov;
109(7):2177-2185.
PMID: 38031804
Mosunetuzumab is a novel bispecific antibody targeting epitopes on CD3 on T cells and CD20 on B cells with the goal of inducing T-cell mediated elimination of malignant B cells....
3.
McGough S, Shamas N, Wang J, Jaber M, Swarup B, Blanchet Zumofen M, et al.
Leuk Lymphoma
. 2023 Oct;
64(14):2269-2278.
PMID: 37840271
A comparison of clinical outcomes in the third or subsequent line (3 L+) of systemic therapy between a real-world data (RWD) external control cohort and a mosunetuzumab single-arm clinical trial...
4.
Casulo C, Larson M, Lunde J, Habermann T, Lossos I, Wang Y, et al.
Lancet Haematol
. 2022 Mar;
9(4):e289-e300.
PMID: 35358443
Background: Novel therapies for relapsed or refractory follicular lymphoma are commonly evaluated in single-arm studies without formal comparison with other treatments or historical controls. Consequently, rigorously defined treatment outcomes informing...
5.
Pappas D, John A, Curtis J, Reed G, Karki C, Magner R, et al.
Rheumatol Ther
. 2016 Oct;
3(1):103-115.
PMID: 27747515
Introduction: In the United States, the recommended starting dose of intravenous tocilizumab (TCZ) is 4 mg/kg every 4 weeks, with an increase to 8 mg/kg based on clinical response for...
6.
Pappas D, Reed G, Saunders K, John A, Shewade A, Greenberg J, et al.
Rheumatol Ther
. 2016 Oct;
2(1):85-96.
PMID: 27747494
Introduction: The aim of this study was to describe factors associated with initiating a biologic as monotherapy vs in combination with a conventional disease-modifying antirheumatic drug (DMARD) in biologic-naive patients...
7.
Harrold L, Reed G, Karki C, Magner R, Shewade A, John A, et al.
Arthritis Care Res (Hoboken)
. 2016 Apr;
68(12):1888-1893.
PMID: 27111064
Objective: To assess whether the time between the last rituximab infusion and initiation of a different biologic agent influenced infection risk in patients with rheumatoid arthritis (RA). Methods: Patients with...
8.
Harrold L, Reed G, Magner R, Shewade A, John A, Greenberg J, et al.
Arthritis Res Ther
. 2015 Sep;
17:256.
PMID: 26382589
Introduction: Patients with active rheumatoid arthritis (RA) despite anti-tumor necrosis factor(anti-TNF)agent treatment can switch to either a subsequent anti-TNF agent or a biologic with an alternative mechanism of action, such...
9.
Harrold L, Reed G, Shewade A, Magner R, Saunders K, John A, et al.
J Rheumatol
. 2015 May;
42(7):1090-8.
PMID: 25934829
Objective: To characterize the real-world effectiveness of rituximab (RTX) in patients with rheumatoid arthritis. Methods: Clinical effectiveness at 12 months was assessed in patients who were prescribed RTX based on...
10.
Gutierrez H, Shewade A, Dai M, Mendoza-Arana P, Gomez-Dantes O, Jain N, et al.
Popul Health Manag
. 2014 Nov;
18(4):265-71.
PMID: 25393442
Lessons learned by countries that have successfully implemented coverage schemes for health services may be valuable for other countries, especially low- and middle-income countries (LMICs), which likewise are seeking to...